Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome

NEW YORK, N.Y. and CAMBRIDGE, Mass. April 24, 2018 – The Jeffrey Modell Foundation, a nonprofit organization for primary immunodeficiency diseases, and X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs, today announced that they are jointly sponsoring a clinical study establishing a genetic screening protocol to help identify patients who have WHIM syndrome (WHIM), a rare, chronic and life-threatening primary immunodeficiency. WHIM is caused by a mutation in a patient’s C-X-C chemokine receptor type 4 (CXCR4) genes.

This entry was posted in Recent Development News: Q2 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »